Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Advanced Micro Devices (AMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Advanced Micro Devices — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Advanced Micro Devices trades at $544.09 (market cap $909.70B). The key difference: Advanced Micro Devices is far larger — about 22.8× Alnylam Pharmaceuticals, Inc.'s market cap, and Advanced Micro Devices is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | AMD | |
|---|---|---|
Market Cap | $39.89B | $909.70B |
Sector | Health | Technology |
52-Week High | $491.22 | $580.91 |
52-Week Low | $278.09 | $146.24 |
Enterprise Value | $38.15B | $901.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
AMD trades at $557.89, up 2.04% today and near its 52-week high, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth, with 2025 revenue reaching $34.64 billion and net income surging to $4.34 billion, though valuation ratios like P/E of 185.96 indicate premium pricing. Recent earnings beats and positive AI-driven news fuel investor optimism.
Outlook remains positive due to AI demand and earnings momentum, but high valuations and intense competition pose risks. Analyst consensus is strongly bullish with a $508.24 price target, though the stock trades above this, suggesting near-term caution amid long-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Advanced Micro Devices
Advanced Micro Devices, Inc. (AMD) produces semiconductor products and devices. The Company offers products such as microprocessors, embedded microprocessors, chipsets, graphics, video and multimedia products and supplies it to third-party foundries, as well as provides assembling, testing, and packaging services. AMD serves customers worldwide.
Read more on AMD →
